Breaking News

Cangene Obtains Alzheimer’s Technology from UBC

February 22, 2013

Aims to advance an immune therapeutic treatment

Cangene has obtained commercial rights to a new technology targeting Alzheimer's Disease (AD) developed at The University of British Columbia (UBC). Following the successful research collaboration with the inventor, Dr. Neil Cashman at UBC, Cangene aims to advance an immune therapeutic treatment approach by targeting the toxic form of amyloid-beta with the potential to directly impact the disease’s mechanism of action.
"We are pleased to have the opportunity to collaborate with Dr. Cashman, who is an expert in misfolded protein diseases and help advance his ground-breaking research in Alzheimer's disease" said Dr. Laura Saward, Cangene's chief scientific officer. "While this work is in its early stages, it is showing promise for the development of a novel immunotherapy to address this devastating disease and fits Cangene's refocused strategy."
"This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic," said Dr. J.P. Heale, associate director of UBC's University-Industry Liaison Office. "The partnerships developed to advance Dr. Cashman 's outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.